Large state-wide variation (10.2-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2016 ^a indicates ≥1.50 SD (19.2) from the mean (34.... حسب Luke R. Cavanah (19022435)

The minimal data set 1. حسب Esete Habtemariam Fenta (9727779)

Treatment with vitamin D3 reduced the viability of cancer cell lines: <i>1A & 1B.</i> حسب Vidya G. Bettada (22208808)

"…Very minimal cytotoxic effect (<10% cell death) was observed at the highest concentration of vitamin D3 tested (i.e., 400µM). 1C. Liver cancer cell line Hep 3B exposed to increasing concentrations of vitamin D3 showed a dose-dependent increase in cytotoxic effect beginning from 31.25µM; 1D. …"

Time course of optical coherence tomography and fundus findings in a representative non-recurrent eye. حسب Yasuyuki Sotani (20114144)

Epac1 expression in the hearts of NTG and Epac1TG. حسب Yoshiki Ohnuki (576298)

الموضوعات:

Fig 7 - حسب Keith Fraser (1868587)

Fig 6 - حسب Keith Fraser (1868587)

Annual number of outpatient visits in recurrence and non-recurrence groups. حسب Yasuyuki Sotani (20114144)

Growth of <i>Spirulina</i> spp. at 450nm for different temperature. حسب Maha Rehman (17114332)

Clinical course of patient no. حسب Kazuyoshi Ohkawa (836847)

Magnification x2 of Fig 1B. حسب Huan W. Yang (19746645)

"…At 5 dpi, there was a significant increase in p65 NF-κB activation, including protein nuclear translocation and phosphorylation, synchronous with the induction of <i>IL-6</i>, <i>IFN-γ</i> and <i>IL-8</i> expression in <i>L</i>. …"

Estimated coefficients from the SARIMA model of new COVID-19 deaths assuming a gradual effect following the implementation of two ETSs and one executive order in Oregon. حسب Raul Cruz-Cano (3751321)

Annual treatment frequencies in recurrence and non-recurrence groups. حسب Yasuyuki Sotani (20114144)

"…These significantly decreased to 2.3 ± 2.6, 0.1 ± 0.3, 0.8 ± 1.6, 0.0, and 3.1 ± 2.8 in the first year; 2.1 ± 2.8, 0.4 ± 1.0, 0, 0.1 ± 0.3, and 2.6 ± 2.8 in the second year; and 2.0 ± 2.2, 0, 0.6 ± 1.7, 0.1 ± 0.3, and 2.8 ± 3.5 in the third year (Kruskal–Wallis test, p < 0.001; Dunn’s test, *P < 0.05, **P < 0.01). …"

Time course of central retinal thickness (CRT) in all eyes. حسب Yasuyuki Sotani (20114144)

"…<p>Mean CRT (μm ± standard deviation) significantly decreased from 504.7 ± 118.2 μm preoperatively to 302.5 ± 60.5 at 1 month, 307.5 ± 64.4 at 3 months, 286.8 ± 49.0 at 6 months, 305.3 ± 79.5 at 12 months, 288.8 ± 79.1 at 24 months, and 295.2 ± 87.4 at 36 months (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …"

Annual treatment frequencies in all eyes. حسب Yasuyuki Sotani (20114144)

"…<p>The number of anti-VEGF treatments, STTA, MA-PC, PPV, and total treatments (mean ± SD) significantly decreased from 2.6 ± 1.6, 0.3 ± 0.8, 0.6 ± 0.8, 0.1 ± 0.3, and 3.7 ± 1.7 preoperatively to 0.8 ± 1.9, 0.0 ± 0.2, 0.3 ± 1.0, 0.0, and 1.2 ± 2.2; at year 2 to 0.7 ± 2.0, 0.1 ± 0.6, 0.0 ± 0.2, 0.0 ± 0.2, and 1.0 ± 2.1; and at year 3 to 0.9 ± 2.2, 0.0, 0.2 ± 1.0, 0.0 ± 0.2, and 1.1 ± 3.1 (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …"

Time course of central retinal thickness (CRT) in recurrence and non-recurrence groups. حسب Yasuyuki Sotani (20114144)

"…<p>In the recurrence group, CRT (μm ± standard deviation) significantly decreased from 546.1 ± 117.0 μm preoperatively to 317.1 ± 46.9, 317.8 ± 55.6, 290.8 ± 33.5, 342.9 ± 82.2, 333.0 ± 84.2, and 349.8 ± 76.9 μm at 1, 3, 6, 12, 24, and 36 months, respectively (Kruskal-Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …"

Time course of best-corrected visual acuity (BCVA) in recurrence and non-recurrence groups. حسب Yasuyuki Sotani (20114144)

"…CRT in the recurrence group significantly decreased from 546.1 ± 117.0 μm preoperatively to 317.1 ± 46.9, 317.8 ± 55.6, 290.8 ± 33.5, 342.9 ± 82.2, 333.0 ± 84.2, and 349.8 ± 76.9 μm at 1, 3, 6, 12, 24, and 36 months postoperatively, respectively (Kruskal-Wallis test, p < 0.001). …"

Time course of best-corrected visual acuity (BCVA) in all eyes. حسب Yasuyuki Sotani (20114144)

Annual number of outpatient visits in all eyes. حسب Yasuyuki Sotani (20114144)

"…<p>Mean visit frequency (mean ± standard deviation) significantly decreased from 11.5 ± 4.3 preoperatively to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …"

Normal Anatomy vs. Disharmonic Pathoanatomy. حسب James M. Friedman (22522150)